Results from this trial for patients with non-clear cell renal cell carcinoma (RCC) or sarcomatoid RCC were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019.
The combination of atezolizumab and bevacizumab has been shown to be effective in the treatment of clear cell RCC. However, there is an unmet need for an effective and safe treatment for patients with non-clear cell RCC and sarcomatoid RCC. This phase 2 trial assessed the safety and efficacy of the atezolizumab plus bevacizumab combination in patients with non-clear cell RCC and patients with sarcomatoid RCC with more than 20% sarcomatoid differentiation.
This study showed that the atezolizumab plus bevacizumab combination was safe and effective in non-clear cell RCC and sarcomatoid RCC, with an objective response rate of 31%.